Atomwise's X-37 spinout gets $14.5 million to launch AI discovery efforts
The folks behind Atomwise’s spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures to back those missions.
X-37 uses Atomwise’s AI platform to identify drug targets and – unlike the parent company, which largely sticks to computers – bring those into a wet lab and preclinical testing. In addition to AI professionals, it’s led in by part by drug developers from Velocity Pharmaceutical Development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.